靶向CEA的[68Ga]Ga-纳米抗体用于结直肠癌的免疫PET:从基础到临床
研究开发了靶向癌胚抗原(CEA)的新型纳米抗体示踪剂[68Ga]Ga-HNI01,在CEA高表达与低表达肿瘤模型中验证其靶向性后,对9例原发及转移性结直肠癌患者行I期PET/CT研究。结果显示该示踪剂制备快速、安全性好、血液清除快,可清晰显示结直肠癌病灶及小转移灶,肾脏放射性蓄积明显。
要点
- 9例患者注射[68Ga]Ga-HNI01后均未发生不良事件。
- 注射后30分钟即可高对比度显示结直肠癌病灶。
- 肾脏放射性蓄积明显,部分患者原发瘤旁非恶性结直肠组织呈强摄取。
核心结论
- [68Ga]Ga-HNI01是新型靶向CEA的PET示踪剂,具有优异的药代动力学和良好的剂量学特征。
- [68Ga]Ga-HNI01 PET是检测结直肠癌病灶的有效且便捷的影像工具,尤其适用于识别小转移灶。
- 其对CEA体内高特异性使其成为筛选抗CEA治疗患者的理想工具。
研究设计与样本
- 临床前:用CEA蛋白免疫美洲驼获得纳米抗体HNI01,通过位点特异性偶联[68Ga]Ga与三(羟基吡啶酮)(THP)合成[68Ga]Ga-HNI01。
- 在CEA高表达LS174T和CEA低表达HT-29肿瘤模型中进行小动物PET显像及生物分布研究。
- 临床I期研究纳入9例原发及转移性结直肠癌患者,静脉注射151.21 ± 25.25 MBq [68Ga]Ga-HNI01,于注射后1小时和2小时行PET/CT。
- 患者01-03另于注射后0-40分钟行全身动态PET显像;所有患者在[68Ga]Ga-HNI01显像后1周内行[18F]F-FDG PET/CT。
主要发现
- [68Ga]Ga-HNI01在温和条件下10分钟内成功合成,无需纯化放射化学纯度超过98%。
- 小动物PET显示LS174T肿瘤清晰显影,HT-29肿瘤信号显著较低;注射后2小时LS174T摄取为8.83 ± 3.02%ID/g,HT-29摄取为1.81 ± 0.87%ID/g。
- 所有临床受试者注射[68Ga]Ga-HNI01后未发生不良事件。
- 血液清除快、背景摄取低,注射后30分钟即可高对比度显示结直肠癌病灶;[68Ga]Ga-HNI01 PET可清晰检测肝、肺、胰腺转移灶,在检测小转移灶方面表现更优。
- 肾脏可见明显放射性蓄积,生理性表达CEA受体的正常组织对[68Ga]Ga-HNI01呈轻度摄取;部分患者原发瘤旁非恶性结直肠组织呈强摄取,提示这些健康组织存在异常CEA表达。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: An accurate diagnosis of colorectal carcinoma (CRC) can assist physicians in developing reasonable therapeutic regimens, thereby significantly improving the patient's prognosis. Carcinoembryonic antigen (CEA)-targeted PET imaging shows great potential for this purpose. Despite showing remarkable abilities to detect primary and metastatic CRC, previously reported CEA-specific antibody radiotracers or pretargeted imaging are not suitable for clinical use due to poor pharmacokinetics and complicated imaging procedures. In contrast, radiolabeled nanobodies exhibit ideal characteristics for PET imaging, for instance, rapid clearance rates and excellent distribution profiles, allowing same-day imaging with sufficient contrast. In this study, we developed a novel CEA-targeted nanobody radiotracer, [68 Ga]Ga-HNI01, and assessed its tumor imaging ability and biodistribution profile in preclinical xenografts and patients with primary and metastatic CRC. METHODS: The novel nanobody HNI01 was acquired by immunizing the llama with CEA proteins. [68 Ga]Ga-HNI01 was synthesized by site-specifically conjugating [68 Ga]Ga with tris(hydroxypyridinone) (THP). Small-animal PET imaging and biodistribution studies were performed in CEA-overexpressed LS174T and CEA-low-expressed HT-29 tumor models. Following successful preclinical assessment, a phase I study was conducted on 9 patients with primary and metastatic CRC. Study participants received 151.21 ± 25.25 MBq of intravenous [68 Ga]Ga-HNI01 and underwent PET/CT scans at 1 h and 2 h post injection. Patients 01-03 also underwent whole-body dynamic PET imaging within 0-40 min p.i. All patients underwent [18F]F-FDG PET/CT imaging within 1 week after [68 Ga]Ga-HNI01 imaging. Tracer distribution, pharmacokinetics, and radiation dosimetry were calculated. RESULTS: [68 Ga]Ga-HNI01 was successfully synthesized within 10 min under mild conditions, and the radiochemical purity was more than 98% without purification. Micro-PET imaging with [68 Ga]Ga-HNI01 revealed clear visualization of LS174T tumors, while signals from HT-29 tumors were significantly lower. Biodistribution studies indicated that uptake of [68 Ga]Ga-HNI01 in LS174T and HT-29 was 8.83 ± 3.02%ID/g and 1.81 ± 0.87%ID/g, respectively, at 2 h p.i. No adverse events occurred in all clinical participants after the injection of [68 Ga]Ga-HNI01. A fast blood clearance and low background uptake were observed, and CRC lesions could be visualized with high contrast as early as 30 min after injection. [68 Ga]Ga-HNI01 PET could clearly detect metastatic lesions in the liver, lung, and pancreas and showed superior ability in detecting small metastases. A significant accumulation of radioactivity was observed in the kidney, and normal tissues physiologically expressing CEA receptors showed slight uptakes of [68 Ga]Ga-HNI01. An interesting finding was that strong uptake of [68 Ga]Ga-HNI01 was found in non-malignant colorectal tissues adjacent to the primary tumor in some patients, suggesting abnormal CEA expression in these healthy tissues. CONCLUSION: [68 Ga]Ga-HNI01 is a novel CEA-targeted PET imaging radiotracer with excellent pharmacokinetics and favorable dosimetry profiles. [68 Ga]Ga-HNI01 PET is an effective and convenient imaging tool for detecting CRC lesions, particularly for identifying small metastases. Furthermore, its high specificity for CEA in vivo makes it an ideal tool for selecting patients for anti-CEA therapy.
引用
- Li L, Lin X, Wang L, et al. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside. Eur J Nucl Med Mol Imaging. 2023. PMID: 37382662. doi:10.1007/s00259-023-06313-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。